About Phase Genomics
Phase Genomics is a Healthcare company based in Seattle (United States) founded in 2015. Laboratory and computational services for DNA proximity analysis are provided. Phase Genomics has raised $5.75 million across 19 funding rounds from investors including NIH, Gates Foundation and HHS. Phase Genomics offers products and services including CytoTerra Platform, ProxiMeta Platform, and Proximo Platform. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Genomics. Its legal entity is Phase Genomics, Inc. Its competitors include Candel Therapeutics, StrideBio and Tessera Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Provider of laboratory and computational services and products. The company has developed technology that allows the extraction of information regarding the physical proximity of DNA stretches inside the nucleus from short- or long-read HT sequencing allowing researchers to reconstruct the 3D organization of DNA within the nucleus. Phase Genomics Proximo Hi-C measures the proximity of DNA in vivo and uses that information to scaffold contigs into entire chromosomes, or to deconvolute metagenomes from complex mixtures of environmental DNA.
- Headquarters Seattle, United States
- SectorsHealthcare
- Email••••••••
- Website phasegenomics.com
- Social LinkedIn X Facebook YouTube
- Legal Name Phase Genomics, Inc.
- Total Equity Funding$5.75M (USD)
in 19 rounds
- Latest Funding Round$1.5M (USD), Grant
Mar 2024
- InvestorsNIH
& 8 more
Products & Services of Phase Genomics
Phase Genomics offers a comprehensive portfolio of products and services, including CytoTerra Platform, ProxiMeta Platform, and Proximo Platform.
Tool for cytogenetics analysis and chromosomal abnormality detection
Platform for metagenome deconvolution and microbial host attribution
System for ultra-long-range genome mapping and analysis
Apps and channels of Phase Genomics
its YouTube channel Phase Genomics has 481 subscribers and 21 videos.
Videos from Phase Genomics
The most watched videos on Phase Genomics's YouTube channel, Phase Genomics (481 subscribers). Click a video to play it here.
More on Phase Genomics.
Funding Insights of Phase Genomics
Phase Genomics has successfully raised a total of $5.75M across 19 strategic funding rounds. The most recent funding activity was a Grant round of $1.5 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.75M
- Total Rounds 19
- Last Round Grant — $1.5M
- First Round $1.5M
(Jun 2016)
- Investors Count 9
Latest 10 of 19 funding rounds of Phase Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $1.5M | Grant | – | – | |
| Sep 2023 | $2M | Grant | – | – | |
| Aug 2023 | $2.5M | Grant | – | – | |
| Jun 2023 | $299,132 | Grant | – | – | |
| Mar 2023 | $4.75M | Series A | – | – | – |
| Jun 2022 | $5.5M | Grant | – | – | |
| Jun 2022 | $1.99M | Grant | – | – | |
| May 2021 | $1.93M | Grant | – | – | |
| Apr 2021 | Grant | – | – | ||
| Feb 2021 | $1.7M | Grant | – | – |
9 investors in total: 9 institutional.
Investors in Phase Genomics
Phase Genomics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Gates Foundation and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Climate tech investing and support for early-stage entrepreneurs in North America. | congruentvc.com | |||
Early-stage investments are made in Washington-based startups by WRF Capital. | wrfcapital.com | Seattle, United States | ||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
Cancer research is promoted by Andy Hill CARE Fund in Washington. | 2015 | wacarefund.org | Bothell, United States | |
| niaid.nih.gov | ||||
Genomics research and educational resources are provided. | 1988 | genome.gov | Bethesda, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Phase Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Phase Genomics
17 people are tracked at Phase Genomics (3 in leadership, 6 in board & advisors, 8 in team).
| Name | Role | Group |
|---|---|---|
Ivan Liachko | Founder & CEO | Leadership |
Stephen Eacker | Vice President of Research and Development | Leadership |
Ben Auch | Director Of Metagenomics | Leadership |
Maitreya Dunham | Scientific Advisor | Board & advisors |
Andrew Adey | Scientific Advisor | Board & advisors |
Todd Smith | Business Advisor | Board & advisors |
Jay Shendure | Scientific Advisor | Board & advisors |
Elhanan Borenstein | Scientific Advisor | Board & advisors |
Ken Myer | Business Advisor | Board & advisors |
Emily Reister Morris, Ph.D. | Staff Laboratory Science Lead | Team |
Jonas Grove | Senior Computational Biologist | Team |
Moutusee Islam, PhD | Research Scientist II | Team |
Maika Malig | Research Scientist | Team |
Lauren Burgess | Research Associate III | Team |
Anna Reister Schultz | Project Manager | Team |
Michael VanDyke, Ph.D. | Staff Engineering Lead | Team |
Hayley Mangelson | Staff Bioinformatics Lead | Team |
Complete people profiles for Phase Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Phase Genomics
3 dated milestones of Phase Genomics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Phase Genomics is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Grant, of $1.5M.
Competitors of Phase Genomics
Phase Genomics has 3 listed competitors in our database, 3 of them funded. They include Candel Therapeutics, StrideBio and Tessera Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| candeltx.com | 1999 | United States | $110.3M | 76 | Viral immunotherapies are developed for cancer treatment. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| tesseratherapeutics.com | 2017 | Cambridge, United States | $610M | 149 | New genome engineering technology is provided for treating multiple diseases. |
Detailed competitors of Phase Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Phase Genomics
The website of Phase Genomics (phasegenomics.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▼ 21.2% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Phase Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Phase Genomics
Complete news archive for Phase Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Phase Genomics
Phase Genomics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Phase Genomics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Phase Genomics is a funded company, having raised a total of $5.75M across 19 funding rounds to date. The company's 1st funding round was a Grant of $1.7M, raised on Jun 2016.
Provider of laboratory and computational services and products. The company has developed technology that allows the extraction of information regarding the physical proximity of DNA stretches inside the nucleus from short- or long-read HT sequencing allowing researchers to reconstruct the 3D organization of DNA within the nucleus. Phase Genomics Proximo Hi-C measures the proximity of DNA in vivo and uses that information to scaffold contigs into entire chromosomes, or to deconvolute metagenomes from complex mixtures of environmental DNA.
Phase Genomics's top competitors include Tessera Therapeutics, Candel Therapeutics and StrideBio.
Phase Genomics offers CytoTerra Platform, ProxiMeta Platform, and Proximo Platform.
Phase Genomics has 9 investors. Key investors include NIH, Gates Foundation, HHS, National Cancer Institute, and NHGRI.
Phase Genomics operates through Phase Genomics, Inc..